Go to Home



ProPharma assists biotechnology and pharmaceutical clients with corporate partnering, in-licensing, out-licensing, mergers or acquisitions, drug development, clinical planning, new venture strategic planning, technology assessment and valuations, and financing of early and mid-stage companies.

Recent Deals and Alliances

The Partners of ProPharma actively facilitated the recent alliances:
BioDelivery Sciences International (BDSI) has entered into a license and supply agreement with TTY Biopharm, for the exclusive rights to develop and commercialize BEMA fentanyl (marketed as ONSOLIS in the US) in the Republic of China, Taiwan. Under the agreement, TTY will be responsible for the regulatory filing of BEMA fentanyl in Taiwan as well as future commercialization in that territory. BEMA fentanyl is approved in the US and Canada, under the trade name ONSOLIS, for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer. October 8, 2010.
Alfresa Pharmaceutical Corporation of Japan entered into a licensing and supply agreement for development and marketing of tetrabenazine (Xenazine®) in Japan with Canada’s Biovail Corporation, with a view to treating involuntary movement disorders, including Huntington’s disease. ProPharma Partners initiated this deal for Cambridge Laboratories Ltd. When Cambridge Labs were sold to Biovail, ProPharma further assisted Biovail towards completion of this transaction. June 10, 2010.

BioDelivery Sciences International (BDSI) is entering the South Korean market with its pain relief treatment for cancer patients. The Raleigh pharmaceutical company has reached a license and supply agreement with Kunwha Pharmaceutical Co. to develop and commercialize BEMA fentanyl. It is sold in this country as Onsolis. The agreement includes an upfront payment of $300,000, and BDSI could see milestone payments of up to $1.2 million. In addition, the company will receive ongoing royalties based on net sales. Kunwha, which employs a sales force of 150, will be responsible for the regulatory filing in South Korea and commercialization of the pain medication. The product is a bit of film that is applied to the inside of a patient's cheek. Once there it dissolves, releasing fentanyl, a morphine-like drug that delivers a quick dose of pain relief. Onsolis was approved by the FDA for sale in the United States last year to treat adult patients with cancer. It was approved in Canada earlier this month. May 27, 2010

Esperance Pharmaceuticals and Teva Pharmaceuticals enter into a letter of intent to evaluate an early stage anti-cancer development compound. May 25, 2009
AmpliMed Corporation, a cancer therapeutics company, announced today that it has entered into a license agreement with leading Korean-based pharmaceutical company Handok Pharmaceuticals for exclusive rights to its investigational cancer therapeutic Amplimexon(R)in Korea. September 10, 2008.
Ascend Therapeutics Partners with Valeant Pharmaceuticals to promote Migranal® migraine product to OB/GYN physicians, October 2007
Valeant Pharmaceuticals to Partner with ASCEND Therapeutics to Promote Migranal® to OB/GYNs
Gemin X Biotechnologies and Leo Pharma
Gemin X Biotechnologies licenses world wide rights to GMX1777, a novel prodrug therapeutic for the treatment of refractory solid tumors and Lymphomas from Leo Pharma May 2007
ReGen and Metagenics
ReGen signs first commercial deal for Colostrinin
Cytogen Corporation and Inpharma AS
Cytogen Corporation licenses exclusive North American rights to Capsohol®, a treatment for the relief of pain associated with oral mucositis from InPharma AS
Asterand and BTG Adobe Acrobat PDF Document
BTG licenses analgesic compounds from Asterand
Sanochemia and Avigen Adobe Acrobat PDF Document
Avigen partners Sanochemia's tolperisone for the North American market.
ProPharma and Biolink International form Partnership
New partnership expands services and expertise
Miikana Therapeutics and Roche Adobe Acrobat PDF Document
Miikana licenses Phase II anticancer compound from Roche
Pfizer and Meridica Adobe Acrobat PDF Document
Pfizer's acquisition of Meridica
Enzon Pharmaceuticals, Inc. and Pharmagene
Cystic fibrosis treatment development collaboration
Cerylid Biosciences and Anadys Pharmaceuticals Adobe Acrobat PDF Document
Natural product chemistry collaboration
Metabolex and Yamanouchi (now known as Astellas) Adobe Acrobat PDF Document
Diabetes target discovery partnership
Replidyne, Inc and Sequoia Sciences Adobe Acrobat PDF Document
Compound/access screening collaboration
Daiichi Pharmaceuticals and Rigel Pharmaceuticals Adobe Acrobat PDF Document
Cancer focused drug discovery partnership

Recent News

South Korea Pharma Out-Licensing
Opportunities for Development Stage Life Science Companies in North America
and Europe

In June 2012, Paulo Rangel participated in the annual South Korean Global Bio & Medical Forum 2012 (GBF 2012) and the G-Trade partnering conference. Both conferences focused on establishing relationships with innovative Korean companies.

GBF 2012 was organized by the Korea Trade Investment Promotion Agency (KOTRA) and included life science companies from throughout South Korea. G-Trade was hosted by KOTRA and the government of the Gyeonggi-do province to introduce companies from that province to international companies.

Paulo met with large Korean Pharma and innovative biotech, device and nutraceutical companies. The Korean companies participating in these companies are eager to work with U.S. and European companies to in-license products and to establish distribution channels for their products in regions outside of Korea.

South Korea, with a population of approximately 50 million, state of the art R&D capabilities, sophisticated regulatory organizations and a growing economy, offers exciting opportunities for out-licensing novel therapeutics and devices and for in-licensing products discovered by Korean companies.

ProPharma Partners and Focus Therapeutics establish a South Korean licensing initiative for introducing late stage and marketed therapeutic products and medical devices into the South Korean market: Focus Therapeutics, LLC is a life science business development firm exclusively focused on bilateral technology and product transfer between US and Asian Pacific regions, particularly South Korea. ProPharma Partners and Focus Therapeutics will leverage their respective expertise to identify products in the US and Europe that would address unmet needs in Korea and introduce those opportunities to appropriate Korean companies who could obtain regulatory approval and commercialize the products in the South Korean market. January 15, 2011
AusBiotech Industry WorkshopAdobe Acrobat PDF Document In Brisbane Monday 27 July 2009; Melbourne Wednesday 29 July 2009
ProPharma Partner, James Chubb, will chair a session on Wednesday, June 18 10:15-11:45 during the annual BIO meeting in San Diego. The session is entitled Extracting Value out of Your Early-Stage Pipeline. The Panelists will include Peter Condon, Genentech; Hugh Cowley, GSK; Don deBethizy, Targacept; and Gordon Shore, GeminX.
ProPharma Partner, Paulo Rangel, will participate on a panel at the Arrowhead Symposium entitled Pharma/Biotech Product Life Cycle Management Strategies at the La Jolla Marriott hotel February 27-28, 2008. Paulo's presentation is entitled: Targeted Drug Delivery as a means to improve drugs and manage product life cycle - A case study of the lung.
BIO (Biotechnology Industry Organization) has selected ProPharma for the 5th consecutive year to assist in organizing the 5th annual BIO-Asia Partnering Conference in Tokyo, January, 28-29 2008
BioAsia Partnering ConferenceBIO (Biotechnology Industry Organization) has selected ProPharma to assist in organizing the 4th annual BIO-Asia Partnering Conference scheduled for January 29 -30 2007.
ProPharma participates on partnering conference panel entitled "Strategies for Successful Partnering" at the San Jose BioCenter November 9 2006
ProPharma invited to present on "Product In-licensing Strategies" during the March 10, 2005 annual meeting of the Canadian Healthcare Licensing Association
ProPharma Presents at the BioPartnering North America Conference in Vancouver on February 8-10. 2004
ProPharma will be discussing its business development experience and strategies during the conference session entitled "The Dynamics of Asian Deal Making"
ProPharma Provides Organizational Support to BIO
BIO ( Biotechnology Industry Organization) engaged ProPharma to assist in the organization of BIOAsia, an industry partnering meeting to be held February 2-3, 2004 in Tokyo, Japan.
+1 510 681 4445